To test whether CIRBP levels can function as a prognosis factor, we explored CIRBP transcript prevalence in ER+PR+ patients with primary infiltrating ductal carcinoma and negative lymph node status. The gene discussed is ESR1; the disease is invasive ductal breast carcinoma.